Fairmount Funds Management is a Philadelphia-based investment firm specializing in the biotechnology and life sciences sectors. The firm typically invests in Series A, Series B, and post-IPO equity rounds, focusing on promising new therapies. Their investment strategy is geared towards companies developing innovative treatments and technologies in the biotech space.
Notable portfolio companies include Cogent Biosciences, Interius BioTherapeutics, Terns Pharmaceuticals, and Zenas BioPharma. Fairmount Funds Management prides itself on its deep industry expertise and offers strategic guidance and support to its portfolio companies. The firm’s key partners bring extensive experience from leading biotech firms, ensuring a robust network and valuable insights for the companies they invest in.
Portfolio Snapshot
Observed round participation, including acquisitions and grants. Current holdings, investor exits, and write-offs are not established.
